Display options
Cite
Buas MF, Gu H, Djukovic D, et al. Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett's esophagus, and high-grade dysplasia/esophageal adenocarcinoma. Metabolomics. 2017;13(3)doi: 10.1007/s11306-016-1154-y.
Buas, M. F., Gu, H., Djukovic, D., Zhu, J., Onstad, L., Reid, B. J., Raftery, D., & Vaughan, T. L. (2017). Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett's esophagus, and high-grade dysplasia/esophageal adenocarcinoma. Metabolomics : Official journal of the Metabolomic Society, 13(3), . https://doi.org/10.1007/s11306-016-1154-y
Buas, Matthew F, et al. "Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett's esophagus, and high-grade dysplasia/esophageal adenocarcinoma." Metabolomics : Official journal of the Metabolomic Society vol. 13,3 (2017). doi: https://doi.org/10.1007/s11306-016-1154-y
Buas MF, Gu H, Djukovic D, Zhu J, Onstad L, Reid BJ, Raftery D, Vaughan TL. Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett's esophagus, and high-grade dysplasia/esophageal adenocarcinoma. Metabolomics. 2017 Mar;13(3). doi: 10.1007/s11306-016-1154-y. Epub 2017 Jan 20. PMID: 28190989; PMCID: PMC5295138.
Copy Download .nbib Format: NLM
Share it on

Metabolomics. 2017 Mar;13(3). doi: 10.1007/s11306-016-1154-y. Epub 2017 Jan 20.

Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett's esophagus, and high-grade dysplasia/esophageal adenocarcinoma.

Metabolomics : Official journal of the Metabolomic Society

Matthew F Buas, Haiwei Gu, Danijel Djukovic, Jiangjiang Zhu, Lynn Onstad, Brian J Reid, Daniel Raftery, Thomas L Vaughan

Affiliations

  1. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109 USA; Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, 14263 USA.
  2. Northwest Metabolomics Research Center, Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, WA 98109 USA.
  3. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109 USA.
  4. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109 USA; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 USA.
  5. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109 USA; Northwest Metabolomics Research Center, Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, WA 98109 USA.
  6. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109 USA; Department of Epidemiology, University of Washington School of Public Health, Seattle, WA, 98109 USA.

PMID: 28190989 PMCID: PMC5295138 DOI: 10.1007/s11306-016-1154-y

Abstract

INTRODUCTION/OBJECTIVES: Incidence of esophageal adenocarcinoma (EA), an often fatal cancer, has increased sharply over recent decades. Several important risk factors (reflux, obesity, smoking) have been identified for EA and its precursor, Barrett's esophagus (BE), but a key challenge remains identifying individuals at highest risk, since most with reflux do not develop BE, and most with BE do not progress to cancer. Metabolomics represents an emerging approach for identifying novel biomarkers associated with cancer development.

METHODS: We used targeted liquid chromatography-mass spectrometry (LC-MS) to profile 57 metabolites in 322 serum specimens derived from individuals with gastroesophageal reflux disease (GERD), BE, high-grade dysplasia (HGD), or EA, drawn from two well-annotated epidemiologic parent studies.

RESULTS: Multiple metabolites differed significantly (P<0.05) between BE versus GERD (n=9), and between HGD/EA versus BE (n=4). Several top candidates (FDR q≤0.15), including urate, homocysteine, and 3-nitrotyrosine, are linked to inflammatory processes, which may contribute to BE/EA pathogenesis. Multivariate modeling achieved moderate discrimination between HGD/EA and BE (AUC=0.75), with less pronounced separation for BE versus GERD (AUC=0.64).

CONCLUSION: Serum metabolite differences can be detected between individuals with GERD versus BE, and between those with BE versus HGD/EA, and may help differentiate patients at different stages of progression to EA.

Keywords: Barrett’s esophagus; esophageal adenocarcinoma; gastroesophageal reflux disease; metabolomics; risk stratification; serum biomarkers

Conflict of interest statement

Statement : D.R. holds equity and an executive role in Matrix-Bio, Inc. (IN, USA). The authors have no other potential conflicts of interest to disclose.

References

  1. Nature. 2009 Feb 12;457(7231):910-4 - PubMed
  2. J Clin Oncol. 2015 Nov 20;33(33):3880-6 - PubMed
  3. Cancer Res. 2010 Nov 15;70(22):9129-36 - PubMed
  4. Electrophoresis. 2013 Oct;34(19):2910-7 - PubMed
  5. Cancer Res. 2010 Nov 1;70(21):8309-18 - PubMed
  6. PLoS One. 2012;7(1):e30181 - PubMed
  7. Bioanalysis. 2012 Feb;4(4):431-51 - PubMed
  8. World J Gastroenterol. 2005 May 14;11(18):2697-703 - PubMed
  9. J Stat Softw. 2010;33(1):1-22 - PubMed
  10. Ann Epidemiol. 2009 Jan;19(1):15-24 - PubMed
  11. Eur J Gastroenterol Hepatol. 2004 Nov;16(11):1199-205 - PubMed
  12. Nat Med. 2014 Oct;20(10):1193-8 - PubMed
  13. Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1441-52 - PubMed
  14. Cancer Epidemiol Biomarkers Prev. 1994 Apr-May;3(3):225-8 - PubMed
  15. PLoS Med. 2007 Feb;4(2):e67 - PubMed
  16. Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2182-201 - PubMed
  17. Am J Gastroenterol. 2002 Aug;97(8):1888-95 - PubMed
  18. Xenobiotica. 1999 Nov;29(11):1181-9 - PubMed
  19. Clin Cancer Res. 2009 Jan 15;15(2):431-40 - PubMed
  20. Eur J Cancer. 2013 Nov;49(17):3625-37 - PubMed
  21. World J Surg Oncol. 2012 Dec 15;10:271 - PubMed
  22. Cancer Epidemiol. 2009 Jul;33(1):79-84 - PubMed
  23. Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):631-40 - PubMed
  24. Int J Cancer. 2016 Jun 15;138(12):2813-9 - PubMed
  25. Am J Surg. 2003 Mar;185(3):232-8 - PubMed
  26. Bioinformatics. 2005 Oct 15;21(20):3940-1 - PubMed
  27. J Clin Epidemiol. 2014 Aug;67(8):850-7 - PubMed
  28. Am J Gastroenterol. 2013 Mar;108(3):353-62 - PubMed
  29. PLoS Med. 2015 Jan 29;12 (1):e1001780 - PubMed
  30. Rapid Commun Mass Spectrom. 2010 Oct 30;24(20):3057-62 - PubMed
  31. Cancer Lett. 2014 Nov 1;354(1):122-31 - PubMed
  32. Cancer Cell. 2015 Feb 9;27(2):271-85 - PubMed
  33. Cancer Prev Res (Phila). 2012 Sep;5(9):1115-23 - PubMed
  34. Biofactors. 2009 Mar-Apr;35(2):120-9 - PubMed
  35. PLoS One. 2014 Jan 24;9(1):e86223 - PubMed
  36. Nat Cell Biol. 2015 Dec;17 (12 ):1523-35 - PubMed
  37. J Thorac Cardiovasc Surg. 2011 Feb;141(2):469-75, 475.e1-4 - PubMed
  38. Cancer Prev Res (Phila). 2015 Sep;8(9):845-56 - PubMed
  39. Expert Rev Mol Diagn. 2008 Sep;8(5):617-33 - PubMed
  40. Gastroenterology. 2007 Aug;133(2):403-11 - PubMed
  41. Int J Cancer. 2015 Feb 15;136(4):915-27 - PubMed
  42. Nat Rev Gastroenterol Hepatol. 2015 Apr;12(4):243-8 - PubMed
  43. Clin Cancer Res. 2010 Dec 1;16(23):5835-41 - PubMed
  44. Carcinogenesis. 1998 Aug;19(8):1445-9 - PubMed
  45. PLoS One. 2013;8(2):e56884 - PubMed
  46. J Proteome Res. 2014 Sep 5;13(9):4120-30 - PubMed
  47. Clin Gastroenterol Hepatol. 2013 Feb;11(2):138-44.e2 - PubMed
  48. PLoS One. 2014 Jul 30;9(7):e103508 - PubMed
  49. Am J Clin Nutr. 2013 Apr;97(4):827-34 - PubMed
  50. Mol Carcinog. 2008 Apr;47(4):275-85 - PubMed
  51. Gastrointest Endosc Clin N Am. 2003 Apr;13(2):369-97 - PubMed
  52. Nat Genet. 2014 Aug;46(8):837-43 - PubMed
  53. Am J Gastroenterol. 2005 Apr;100(4):886-95 - PubMed
  54. Clin Gastroenterol Hepatol. 2015 Oct;13(10 ):1730-1737.e9 - PubMed
  55. Future Oncol. 2012 Oct;8(10):1207-10 - PubMed
  56. Nat Rev Cancer. 2010 Feb;10(2):87-101 - PubMed
  57. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Sep 1;966:59-69 - PubMed
  58. Nat Rev Gastroenterol Hepatol. 2011 Nov 22;9(1):15-22 - PubMed
  59. Am J Gastroenterol. 2009 Apr;104(4):834-42 - PubMed
  60. Nat Genet. 2014 Aug;46(8):806-7 - PubMed
  61. Clin Transl Med. 2012 Aug 15;1(1):16 - PubMed
  62. Cancer Res. 2006 Nov 15;66(22):10795-804 - PubMed

Publication Types

Grant support